Borgan F, Laurikainen H, Veronese M, et al. - In this cross-sectional case-control study of 58 males, researchers examined cannabinoid 1 receptor (CB1R, G-protein–coupled receptors expressed on presynaptic nerve terminals of excitatory and inhibitory neurons throughout the cortex, thalamus, hippocampus, and striatum) availability in first-episode psychosis without the confounds of illness chronicity or the use of illegal substances or antipsychotics. In antipsychotic-treated and untreated cohorts in relation to matched controls, the availability of CB1R was lower. Exploratory analyses intimated that in male patients, greater decreases in CB1R levels were related to greater symptom severity and poorer cognitive functioning. These findings imply that for the treatment of psychotic disorders, CB1R could be a possible target.